|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...28293031323334353637383940» |
- clozapine / Generic mfg.
Enrollment change: ATOMICS: Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia (clinicaltrials.gov) - Nov 16, 2011
P=N/A, N=8, Terminated, Sponsor: North Shore Long Island Jewish Health System
N=12 --> 8
- Clinical: Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective Study (clinicaltrials.gov) - Nov 15, 2011
P=N/A, N=152, Completed, Sponsor: Central South University
- |||| quetiapine extended-release / Generic mfg.
Trial completion: eXtRa: Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia (clinicaltrials.gov) - Nov 13, 2011
P4, N=75, Completed, Sponsor: AstraZeneca
N=12 --> 8 Recruiting --> Completed
- quetiapine extended-release / Generic mfg.
Trial termination: Quetiapine XR in Schizophrenic Patients (clinicaltrials.gov) - Nov 9, 2011
P3, N=5, Terminated, Sponsor: Hannover Medical School
Recruiting --> Completed Recruiting --> Terminated; Planned number of 30 subjects could not be recruited during recruitment phase.
- |||||||||| Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes
New P3 trial: A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia (clinicaltrials.gov) - Nov 8, 2011
P3, N=623, Active, not recruiting, Sponsor: Alkermes
- | Rexulti (brexpiprazole) / Lundbeck, Otsuka
Trial completion: A Study Evaluating the of OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects (clinicaltrials.gov) - Nov 8, 2011
P1, N=45, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting --> Terminated; Planned number of 30 subjects could not be recruited during recruitment phase. Active, not recruiting --> Completed
- New P2 trial: Repetitive Transcranial Magnetic Stimulation (rTMS) and P50 Evoked Potential Component (clinicaltrials.gov) - Nov 6, 2011
P2, N=30, Completed, Sponsor: University Hospital, Caen
- clozapine / Generic mfg.
Trial completion: Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) (clinicaltrials.gov) - Nov 3, 2011
P=N/A, N=85, Completed, Sponsor: University of Aarhus
Active, not recruiting --> Completed Recruiting --> Completed
- || Enrollment change: The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics (clinicaltrials.gov) - Oct 30, 2011
P1, N=59, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=30 --> 59
- ||| Trial completion: The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics (clinicaltrials.gov) - Oct 30, 2011
P1, N=59, Completed, Sponsor: AstraZeneca
N=30 --> 59 Active, not recruiting --> Completed
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
New P4 trial: Brain Myelination Effects of Paliperidone Palmitate Versus Oral Risperidone in First Episode Schizophrenia (clinicaltrials.gov) - Oct 20, 2011
P4, N=50, Not yet recruiting, Sponsor: University of California, Los Angeles
- methamphetamine / Generic mfg.
Enrollment closed: Development of a Family-Based Treatment for Adolescent Methamphetamine Use (clinicaltrials.gov) - Oct 20, 2011
P1, N=60, Active, not recruiting, Sponsor: Oregon Research Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| quetiapine extended-release / Generic mfg.
Trial completion: SereNIS: Seroquel XR in the Long Term Treatment of Schizophrenia (clinicaltrials.gov) - Oct 20, 2011
P=N/A, N=1606, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | quetiapine / Generic mfg.
Trial completion: Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients (clinicaltrials.gov) - Oct 20, 2011
P4, N=30, Completed, Sponsor: University of Regensburg
Active, not recruiting --> Completed Recruiting --> Completed
- | amisulpride / Generic mfg.
New P4 trial: Optimisation of Antipsychotic Drug Use in Older People (clinicaltrials.gov) - Oct 17, 2011
P4, N=120, Recruiting, Sponsor: Institute of Psychiatry, London
- |||| Trial completion: FYS Study: Epidemiological, Multicentre, Cross-sectional Study in a Clinical Practice Environment, About the Relationship Between Functioning Status and the Quality of Sleep Perceived by Schizophrenic Outpatients in Spain (clinicaltrials.gov) - Oct 16, 2011
P4, N=709, Completed, Sponsor: Janssen-Cilag, S.A.
Recruiting --> Completed Not yet recruiting --> Completed
- asenapine / Generic mfg.
New P4 trial: Once-Daily Asenapine for Schizophrenia (clinicaltrials.gov) - Oct 13, 2011
P4, N=30, Not yet recruiting, Sponsor: Duke University
- Trial completion: Implementing Effective, Collaborative Care for Schizophrenia (EQUIP-2) (clinicaltrials.gov) - Oct 13, 2011
P=N/A, N=1067, Completed, Sponsor: Department of Veterans Affairs
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||| quetiapine extended-release / Generic mfg.
Trial completion: NIS to Observe Improvement in Global Assessment of Functioning in Patients With Schizophrenia (clinicaltrials.gov) - Oct 12, 2011
P=N/A, N=106, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| risperidone / Generic mfg.
New P2 trial: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia (clinicaltrials.gov) - Oct 10, 2011
P2, N=60, Recruiting, Sponsor: PharmaNeuroBoost N.V.
- |||| risperidone / Generic mfg.
Trial completion, Adverse events: A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children (clinicaltrials.gov) - Oct 10, 2011
P4, N=244, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| New P3 trial: Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate (clinicaltrials.gov) - Oct 5, 2011
P3, N=142, Completed, Sponsor: Janssen-Cilag Farmaceutica Ltda.
- | pregnenolone / Duke University Health System
Trial completion: Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia (clinicaltrials.gov) - Oct 4, 2011
P2/3, N=120, Completed, Sponsor: National Research Foundation, Singapore
Recruiting --> Completed Recruiting --> Completed
- Enrollment open: AHCM: Addiction Housing Case Management for Homeless Veterans (clinicaltrials.gov) - Oct 3, 2011
P=N/A, N=400, Recruiting, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Not yet recruiting --> Recruiting
- Enrollment closed: Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE) (clinicaltrials.gov) - Oct 3, 2011
P2, N=280, Active, not recruiting, Sponsor: Kaiser Permanente
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- citalopram / Generic mfg.
Enrollment open, HEOR, Cost effectiveness: ACTIONS: Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia (clinicaltrials.gov) - Sep 28, 2011
P4, N=358, Recruiting, Sponsor: Imperial College London
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| quetiapine extended-release / Generic mfg.
Trial completion, HEOR: PASQAL: Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia (clinicaltrials.gov) - Sep 21, 2011
P=N/A, N=150, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- donepezil / Generic mfg., ziprasidone / Generic mfg.
Trial termination: The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia (clinicaltrials.gov) - Sep 18, 2011
P2, N=50, Terminated, Sponsor: Birte Glenthoj
Active, not recruiting --> Completed No longer recruiting --> Terminated; No more funding
- |||| nelonicline (ABT-126) / AbbVie
Trial completion: Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia (clinicaltrials.gov) - Sep 18, 2011
P2, N=207, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
No longer recruiting --> Terminated; No more funding Active, not recruiting --> Completed
- quetiapine / Generic mfg.
Enrollment change: Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia (clinicaltrials.gov) - Sep 15, 2011
P=N/A, N=46, Completed, Sponsor: Birte Glenthoj
Active, not recruiting --> Completed N=80 --> 46
- |||||||||| lurasidone / Generic mfg.
New P3 trial: PEARL Schizophrenia Maintenance (clinicaltrials.gov) - Sep 15, 2011
P3, N=285, Completed, Sponsor: Sunovion
- quetiapine / Generic mfg.
Trial completion: Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia (clinicaltrials.gov) - Sep 15, 2011
P=N/A, N=46, Completed, Sponsor: Birte Glenthoj
N=80 --> 46 Active, not recruiting --> Completed
- Clopixol (zuclopenthixol) / Lundbeck
Trial completion, Adverse events: Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia (clinicaltrials.gov) - Sep 15, 2011
P=N/A, N=56, Completed, Sponsor: Birte Glenthoj
Active, not recruiting --> Completed No longer recruiting --> Completed
- Trial completion: Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia (clinicaltrials.gov) - Sep 14, 2011
P=N/A, N=52, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed Active, not recruiting --> Completed
- Adherence: SPERA-S: Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia (clinicaltrials.gov) - Sep 11, 2011
P=N/A, N=280, Not yet recruiting, Sponsor: University of Cagliari
- |||||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
New P3 trial: ARRIVE US: Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole (clinicaltrials.gov) - Sep 11, 2011
P3, N=504, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
- ||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion: ASPIRE: Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia (clinicaltrials.gov) - Sep 8, 2011
P3, N=843, Completed, Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Circadin (melatonin prolonged release) / Lundbeck, Neurim, Flynn Pharma, Grupo Insud, Biocodex, Kuhnil Pharma
New P4 trial: SMART: Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia (clinicaltrials.gov) - Sep 7, 2011
P4, N=86, Active, not recruiting, Sponsor: Lone Baandrup
- ||||||| lurasidone / Generic mfg.
Trial completion: SWITCHCore: A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents (clinicaltrials.gov) - Sep 6, 2011
P3, N=244, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | olanzapine / Generic mfg., sertraline / Generic mfg.
New P4 trial: STOP-PD: Sustaining Remission of Psychotic Depression (clinicaltrials.gov) - Aug 30, 2011
P4, N=392, Recruiting, Sponsor: Weill Medical College of Cornell University
- Clinical: rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia (clinicaltrials.gov) - Aug 27, 2011
P=N/A, N=20, Recruiting, Sponsor: Jeonbuk Provincial Maeumsarang Hospital
- | New P2 trial: e-CAeSAR: Evaluation of a Cognitive Adaptive E-treatment in Schizophrenia-diagnosed Adults (clinicaltrials.gov) - Aug 23, 2011
P2, N=150, Recruiting, Sponsor: Cate Stasio
- | PF-05180999 / Pfizer
New P1 trial: A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults (clinicaltrials.gov) - Aug 23, 2011
P1, N=29, Completed, Sponsor: Pfizer
- Enrollment open: Pain and Schizophrenia (clinicaltrials.gov) - Aug 23, 2011
P=N/A, N=100, Recruiting, Sponsor: University Hospital, Strasbourg, France
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Enrollment change: PLEASURE: Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia (clinicaltrials.gov) - Aug 16, 2011
P=N/A, N=231, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=500 --> 231
- | eltoprazine (DU 28853) / Amarantus BioSci, PsychoGenics, ReqMed
Enrollment open: Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults (clinicaltrials.gov) - Aug 16, 2011
P2, N=50, Recruiting, Sponsor: PsychoGenics Inc.
N=500 --> 231 Not yet recruiting --> Recruiting
- ||| Trial completion: PLEASURE: Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia (clinicaltrials.gov) - Aug 16, 2011
P=N/A, N=231, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| lurasidone / Generic mfg.
Trial completion: PEARL 3 Ext: Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia (clinicaltrials.gov) - Aug 15, 2011
P3, N=240, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| lurasidone / Generic mfg.
Trial completion: Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia (clinicaltrials.gov) - Aug 15, 2011
P3, N=629, Completed, Sponsor: Sunovion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open: Yoga and Aerobic Exercise in Psychosis (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=120, Recruiting, Sponsor: The University of Hong Kong
Active, not recruiting --> Completed Not yet recruiting --> Recruiting